Zusammenfassung
Es ist schon seit langem bekannt, daß man bei primären Hyperlipoproteinämien spezifische krankhafte Veränderungen der Haut (Xanthome) finden kann [10, 13]. Während der letzten Jahre sind molekulare Defekte aufgedeckt worden, die für einige hereditäre Hyperlipoproteinämien verantwortlich sind (Tabelle 1) [5].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Brown MS, Goldstein JL (1983) Lipoprotein receptors in the liver. J Clin Invest 72: 743–747
Brown MS, Goldstein JL (1986) A receptor mediated pathway for cholesterol homeostasis. Science 232: 34–47
Consensus Conference (1985) Lowering blood cholesterol to prevent coronary heart disease. JAMA 253: 2080–2086
European Atherosclerosis Society Study Group (1987) Strategies for the prevention of coronary heart disease: A policy statement of the European Atherosclerosis Society. Eur Heart J 8: 77–88
Goldstein JL, Brown MS (1983) Familial hypercholesterolemia. In: Stanbury JB, Wijngaarden JB, Fredrickson DS, Goldstein JL, Brown MS (eds) The metabolic basis of inherited disease. 5th ed. McGraw-Hill, New York, pp 672–712
Grundy SM (1988) HMgA-CoA reductase inhibitors for treatment of hypercholesterolaemia. N Engl J Med 319: 24–33
Illingworth RD, Baacon S (1989) Treatment of heterozygous familial hypercholesterolaemia with lipid lowering drugs. Atherosclerosis Suppl 9: 121–134
Lipid Research Clinics Program (1984) The Lipid Research Clinics’ Coronary Primary Prevention Trial Results. 1. Reduction in incidence of coronary heart diseases. JAMA 251: 351–364
Mol MJTM, Erkelens DW, Leuven JAG, Schouten JA, Stalenhoef AFH (1986) Effects of synvinolin (MK733) on plasma lipids in familial hypercholesterolemia. Lancet II: 936–939
Parker F (1985) Xanthomas and hyperlipidemias. J Am Acad Dermatol 13: 1–28
Steinberg D, Parthasarathy S, Carew ThE, Khoo JC, Witztum JL (1989) Beyond cholesterol modifications of LDL that increases its atherogenicity. N Engl J Med 320: 915–924
Steinmetz A, Schmitt W, Schuler P, Kleinsorge F, Schneider J, Kaffarnik H (1988) Ultrasonography of Achilles tendons in primary hypercholesterolemia. Comparison with computed tomography. Atherosclerosis 74: 231–239
Vermeer BJ, Van Gent CM, Goslings BM, Polano MK (1979) Xanthomatosis and other clinical findings in patients with elevated levels of very low density lipoprotein. Br J Dermatol 100: 657–662
Watanabe Y, Ito T, Shiomi M, Tsujita Y, Kuroda M, Arai M, Fukami MN, Tamura A (1988) Preventive effect of pravastin sodium, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on coronary atherosclerosis and xanthoma in WHHL rabbits. Biochem Biophys Acta 960: 294–302
Yamamoto A, Matsuzawa Y, Yokoyama S, Funahashi T, Yamamura T, Kishino BI (1986) Effects of probucol on xanthomata regression in familial hypercholesterolemia. Am J Cardiol 57: 29H - 35H
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Vermeer, B.J., Leuven, J.G. (1990). HMG-CoA-Reduktase hemmende Pharmaka bei Xanthomen und Hyperlipoproteinämien. In: Braun-Falco, O., Ring, J. (eds) Vorträge der XII. Fortbildungswoche der Dermatologischen Klinik und Poliklinik der Ludwig-Maximilians-Universität München in Verbindung mit dem Berufsverband der Deutschen Dermatologen e.V. vom 23. bis 28. Juli 1989. Fortschritte der praktischen Dermatologie und Venerologie, vol 12. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-48223-6_60
Download citation
DOI: https://doi.org/10.1007/978-3-642-48223-6_60
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-51962-1
Online ISBN: 978-3-642-48223-6
eBook Packages: Springer Book Archive